Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Intergroup Rhabdomyosarcoma Study: update, november 1978

H M Maurer

    National Cancer Institute Monograph
    |April 1, 1981
    PubMed
    Summary

    Rhabdomyosarcoma treatment in children shows that 2-year chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC) makes post-operative radiation unnecessary for localized tumors. Advanced stages benefit from intensive chemotherapy and irradiation, improving outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

    Sarcoma·2008
    Same author

    Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

    Journal of pediatric hematology/oncology·2002
    Same author

    Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.

    Journal of pediatric hematology/oncology·2002
    Same author

    Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?

    Seminars in pediatric surgery·2001
    Same author

    What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?

    Cancer·2001

    Area of Science:

    • Pediatric Oncology
    • Medical Research
    • Clinical Trials

    Background:

    • The Intergroup Rhabdomyosarcoma Study (1972-1978) enrolled 780 patients to evaluate treatment protocols for rhabdomyosarcoma.
    • Previous treatment paradigms involved surgery and radiation, with chemotherapy's role evolving.

    Purpose of the Study:

    • To assess the necessity of postoperative irradiation in localized rhabdomyosarcoma treated with combination chemotherapy.
    • To compare the efficacy of different intensive chemotherapy regimens in advanced and metastatic rhabdomyosarcoma.
    • To determine relapse-free and overall survival rates across different stages of the disease.

    Main Methods:

    • Patients were stratified into four groups (I-IV) based on disease extent and surgical resection.
    • Group I: Localized tumors treated with VAC chemotherapy post-excision.
    • Groups II-IV: Varied treatment including VAC, vincristine/dactinomycin, adriamycin, and irradiation based on residual disease and metastatic status.

    Main Results:

    • Postoperative irradiation was unnecessary for localized tumors (Group I) receiving 2-year VAC chemotherapy.
    • Intensive chemotherapy regimens (pulse VAC or VAC with adriamycin plus irradiation) achieved 85% tumor regression in Group III and 68-74% in Group IV.
    • Projected 2-year relapse-free survival rates were 83% (Group I), 72% (Group II), 65% (Group III), and 28% (Group IV).

    Conclusions:

    • Combination chemotherapy (VAC) for 2 years can obviate the need for postoperative irradiation in localized rhabdomyosarcoma.
    • Intensive chemotherapy regimens demonstrate significant efficacy in advanced and metastatic rhabdomyosarcoma.
    • Prognoses for patients with local or distant recurrences remain poor, highlighting the need for improved salvage strategies.

    Related Experiment Videos